MAPT and Alzheimer disease: Tau and Aβ peptide biomarkers are now incorporated in the new research diagnostic criteria in order to increase the biological homogeneity in diagnosed AD cases [15,16], and the β-amyloid deposition, pathologic tau, neurodegeneration (A/T/N) classification has recently been proposed as an unbiased biological definition of the disease [17].